Table 3.
Per-protocol summary of month 7 anti-HPV geometric mean titers in subjects who received 3 doses of 9vHPV vaccine.
| Population | N | n | % Seropositive (95% CI) | GMT (95% CI) |
|---|---|---|---|---|
| Anti-HPV 6 | ||||
| 9- through 15-year-old girls | 2805 | 2349 | 99.7 (99.4, 99.9) | 1744.6 (1684.7, 1806.7) |
| 9- through 15-year-old boys | 1239 | 1055 | 99.9 (99.5, 100) | 2085.3 (1984.2, 2191.6) |
| 16- through 26-year-old women | 7260 | 4321 | 99.8 (99.6, 99.9) | 893.7 (873.5, 914.3) |
| Anti-HPV 11 | ||||
| 9- through 15-year-old girls | 2805 | 2350 | 99.9 (99.7, 100) | 1289.7 (1244.3, 1336.8) |
| 9- through 15-year-old boys | 1239 | 1055 | 100 (99.7, 100) | 1469.2 (1397.7, 1544.4) |
| 16- through 26-year-old women | 7260 | 4327 | 100 (99.9, 100) | 669.3 (653.6, 685.4) |
| Anti-HPV 16 | ||||
| 9- through 15-year-old girls | 2805 | 2405 | 99.9 (99.7, 100) | 7159.9 (6919.7, 7408.5) |
| 9- through 15-year-old boys | 1239 | 1076 | 100 (99.7, 100) | 8444.9 (8054.2, 8854.5) |
| 16- through 26-year-old women | 7260 | 4361 | 100 (99.9, 100) | 3159.0 (3088.6, 3231.1) |
| Anti-HPV 18 | ||||
| 9- through 15-year-old girls | 2805 | 2420 | 99.9 (99.6, 100) | 2085.5 (2002.2, 2172.3) |
| 9- through 15-year-old boys | 1239 | 1074 | 100 (99.7, 100) | 2620.4 (2474.3, 2775.2) |
| 16- through 26-year-old women | 7260 | 4884 | 99.8 (99.7, 99.9) | 809.9 (789.2, 831.1) |
| Anti-HPV 31 | ||||
| 9- through 15-year-old girls | 2805 | 2397 | 100 (99.8, 100) | 1883.3 (1811.3, 1958.1) |
| 9- through 15-year-old boys | 1239 | 1069 | 100 (99.7, 100) | 2173.5 (2057.0, 2296.6) |
| 16- through 26-year-old women | 7260 | 4806 | 99.8 (99.6, 99.9) | 664.8 (647.4, 682.6) |
| Anti-HPV 33 | ||||
| 9- through 15-year-old girls | 2805 | 2418 | 99.9 (99.7, 100) | 960.6 (927.5, 994.9) |
| 9- through 15-year-old boys | 1239 | 1076 | 100 (99.7, 100) | 1178.6 (1120.9, 1239.4) |
| 16- through 26-year-old women | 7260 | 5056 | 99.7 (99.5, 99.8) | 419.2 (409.6, 429.1) |
| Anti-HPV 45 | ||||
| 9- through 15-year-old girls | 2805 | 2430 | 99.8 (99.6, 100) | 728.7 (697.6, 761.2) |
| 9- through 15-year-old boys | 1239 | 1079 | 100 (99.7, 100) | 841.7 (790.0, 896.7) |
| 16- through 26-year-old women | 7260 | 5160 | 99.6 (99.4, 99.7) | 254.1 (247.0, 261.5) |
| Anti-HPV 52 | ||||
| 9- through 15-year-old girls | 2805 | 2426 | 99.9 (99.7, 100) | 978.2 (942.8, 1015.0) |
| 9- through 15-year-old boys | 1239 | 1077 | 100 (99.7, 100) | 1062.2 (1007.2, 1120.2) |
| 16- through 26-year-old women | 7260 | 4792 | 99.8 (99.6, 99.9) | 382.4 (373.0, 392.0) |
| Anti-HPV 58 | ||||
| 9- through 15-year-old girls | 2805 | 2397 | 99.9 (99.7, 100) | 1306.0 (1259.8, 1354.0) |
| 9- through 15-year-old boys | 1239 | 1072 | 100 (99.7, 100) | 1545.8 (1470.6, 1624.8) |
| 16- through 26-year-old women | 7260 | 4818 | 99.8 (99.6, 99.9) | 489.2 (477.5, 501.2) |
N=number of individuals randomized to the respective vaccination group who received at least 1 injection.
n=number of individuals contributing to the analysis.
mMU=milli-Merck units.
CI=confidence interval.
GMT=geometric mean titers (given in milli-Merck units per milliliter).